

Supplemental Table1. Clinicopathological features of NSCLC patients

Characteristic	n (%)
<i>Age at diagnosis (median 64 years, range 28–82)</i>	
<64 years	51(39)
≥64 years	81(61)
<i>Gender</i>	
Male	104(79)
Female	28(21)
<i>Histologic type</i>	
Adenocarcinoma	77(58)
Acinar	39(51)
Papillary	3(4)
Solid	29(38)
Mucinous	2(3)
Lepidic	4(5)
Squamous cell carcinoma	55(42)
<i>pT</i>	
T1	45(35)
T2	68(53)
T3	11(9)
T4	4(3)
<i>pN</i>	
N0	97(78)
N1	12(10)
N2	15(12)
<i>Differentiation grade</i>	
G1	2(2)
G2	70(56)
G3	53(42)
<i>Stage</i>	
IA	33 (25.4)
IB	40(31)
IIA	17(13)
IIB	17(13)
IIIA	17(13)
IIIB	4(3.1)
IV	2(1.5)

Supplemental Table2. Correlation between molecular alterations of HER2 and its expression/activation in NSCLC patients

		<i>HER2</i>			<i>pHER2</i>		
		Negative	Positive	pvalue	Negative	Positive	pvalue
HER2 FISH	Negative	60	21	0.596	46	30	0.121
	Positive	15	7		17	4	

The correlation between biomarkers was determined using contingency tables with a Fisher's exact test